INBX Inhibrx Biosciences, Inc.
$95.66▲ +7.96%
Healthcare
Other
After hours
$95.66▲ +0.00%
Oct 27, 4:00 PM ET
Volume 373.9K
Avg Volume (10D) 218.4K
Key Metrics & Fundamentals
Market Cap
$1.41B
P/E Ratio
–
Div Yield
0.00%
52W Range
57.30 - 155.29
% vs 50 MA
-7.91%
% vs 200 MA
3.79%
RSI-14
49.5
MACD Histogram
+0.7300
Beta (1Y vs SPY)
2.04
Free Cash Flow
-$29.92M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$30.43M
COGS
–
Operating Exp
$32.15M
Operating Income
-$32.15M
EBIT
-$32.15M
Pretax Income
-$36.65M
Net Income
-$36.65M
EPS (Diluted)
-2.34
Price & Volume History
Loading chart…
Recent News
Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price
Simply Wall St. · Oct 23, 2026 6:16 AM ET
Insiders Load Up on These 2 ‘Strong Buy’ Stocks — Should You Follow Their Footsteps?
TipRanks · Oct 21, 2026 1:54 PM ET
Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?
Simply Wall St. · Oct 14, 2026 10:14 AM ET
Inhibrx Announces Participation in Upcoming Scientific Conferences
PR Newswire · Oct 13, 2026 4:00 PM ET
Inhibrx’s Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
MarketBeat · Oct 2, 2026 8:00 AM ET
Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating
Simply Wall St. · Sep 29, 2026 7:08 AM ET
Inhibrx Biosciences Insider Bought Shares Worth $998,784, According to a Recent SEC Filing
MT Newswires · Sep 28, 2026 5:52 PM ET
Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?
Insider Monkey · Sep 24, 2026 1:07 PM ET
Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing
MT Newswires · Sep 23, 2026 5:01 PM ET
Inhibrx Biosciences Insider Bought Shares Worth $500,000, According to a Recent SEC Filing
MT Newswires · Sep 17, 2026 5:55 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2025
See INBX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.